Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer

Journal of Pain and Symptom Management

Volumn 24, Issue 6, 2002, Pages 598-602

  Pavis, Hilary ^a   Wilcock, Andrew ^a,b   Edgecombe, Jane ^a   Carr, Diane ^a   Manderson, Cathann ^a   Church, Ann ^b   Fisher, Anthony ^b  

^a Hayward Hse Macmillan S P C U   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breakthrough pain; Cancer; Morphine; Nasal drugs; Pain

Indexed keywords

CHITOSAN; MORPHINE;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRY NOSE; FEMALE; HUMAN; MALE; NASAL PRURITUS; NAUSEA; NOSE DISEASE; SEDATION; SIDE EFFECT; SORE THROAT; SYMPTOM; TASTE DISORDER; VERTIGO;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANALGESICS, OPIOID; CHITIN; CHITOSAN; DRUG THERAPY, COMBINATION; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; PILOT PROJECTS;

EID: 0036964531     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00522-5     Document Type: Article

References (17)

1. Hanks G.W.C., De Conno F., Cherny N.et al. Morphine and alternative opioids in cancer pain. the EAPC recommendations Brit J Cancer. 84:2001;587-593.
2. Twycross R.G., Wilcock A., Charlesworth S., Dickman A. Palliative Care Formulary. 2nd Ed:2002;Radcliffe Medical Press, Oxon.
3. Collins S.L., Faura C.C., Moore A., McQuay H.J. Peak plasma concentrations after oral morphine. a systematic review J Pain Symptom Manage. 16:1998;388-402.
4. Wilcock A. New approaches to pain management. Prog in Pall Care. 9:2001;100-101.
5. Soane R.J., Frier M., Perkins A.C.et al. Evaluation of the clearance characteristics of bio-adhesive systems in humans. Int J Pharm. 178:1999;55-65.
6. Illum L., Farraj N.F., Davis S.S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res. 11:1994;1186-1189.
7. West Pharmaceutical Services, data on file.
8. Portenoy R.K., Payne D., Jacobsen P. Breakthrough pain. characteristics and impact in patients with cancer pain Pain. 81:1999;129-134.
9. Swanwick M., Haworth M., Lennard R.F. The prevalence of episodic pain in cancer. survey of hospice patients on admission Palliat Med. 15:2001;9-18.
10. Farrar J.T., Cleary J., Rauck R.et al. Oral transmucosal fentanyl citrate. randomized double- blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients J Natl Cancer Inst. 90:1998;611-616.
11. Christie J.M., Simmonds M., Patt R.et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 16:1998;3238-3245.
12. Wilson J.A., Kendall J.M., Cornelius P. Intranasal diamorphine for paediatric analgesia. assessment of safety and efficacy J Accid Emerg Med. 14:1997;70-72.
13. Striebel H.W., Wessel A., Rieger A., Boerger N. Intranasal fentanyl for breakthrough cancer pain or incident pain. Br J Anaesth. 70:1993;A210,109.
14. Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med. 14:2000;57-58.
15. Illum L., Fisher A.N. Intranasal delivery of peptides and proteins. Adjei A.L., Gupta P.K. Inhalation delivery of therapeutic peptides and proteins. 1997;135-184 Marcel Dekker Inc, New York.
16. Dodane V., Vilivalam V. Pharmaceutical applications of chitosan. Pharm Sci Tech Today. 1:1998;246-253.
17. Baillie S.P., Bateman D.N., Coates P.E., Woodhouse K.W. Age and the pharmacokinetics of morphine. Age Ageing. 18:1989;258-262.